2018년07월20일fri
로그인 | 회원가입
OFF
트위터로 보내기 싸이월드 공감
기사글확대 기사글축소 기사스크랩 이메일문의 프린트하기
OS in Relapsed/Refractory B-cell acute Lymphoblastic leukemia patients receiving Inotuzumab-ozogamicin VS Standard care in Phase3 Study
Hagop M Kantarjian, Daniel J DeAngelo, Anjali S Advani, Michaela Liedtke, Wendy Stock, Nicola Goekbuget, Susan O'Brien, Giovanni Martinelli, Kongming Wang, Tao Wang, M Luisa Paccagnella, Barbara Sleight, Erik Vandendries, Matthias Stelljes
[ 2016년 06월 14일 10시 54분 ]

Background


CD22 is expressed in most (>90%) cases of B-cell acute lymphoblastic leukemia (ALL) and is an attractive target for the treatment of B-cell malignancies. Inotuzumab ozogamicin (InO), a humanized anti-CD22 antibody conjugated to calicheamicin, has demonstrated significantly superior response vs standard care (SC) in the first 218 randomized patients with relapsed/refractory (R/R) ALL in the phase 3 INO-VATE trial.


Aims


To assess overall survival (OS) and progression free survival (PFS) of adults with R/R ALL receiving InO vs SC.


Methods


In this ongoing global, 2-arm, randomized phase 3 trial (NCT01564784), patients with R/R ALL (including ~15% of patients in each arm with Philadelphia-positive ALL) due to receive salvage (S) 1 or 2 therapy were randomized to InO (starting dose 1.8 mg/m2/cycle [0.8 mg/m2 on day 1; 0.5 mg/m2 on days 8 and 15 of a 21–28 day cycle (≤6 cycles)]) or SC (either fludarabine/cytarabine [ara-C]/granulocyte colony-stimulating factor [FLAG], ara-C plus mitoxantrone, or high-dose ara-C). Study was designed with two primary endpoints: 1) OS and 2) complete remission (CR)/CR with incomplete hematologic recovery (CRi) assessed in first 218 patients randomized (results previously presented). Overall study-wise type-I error was controlled by splitting 1-sided α to 0.0125 for each endpoint. Safety was assessed in all patients who received ≥1 dose of study drug. Per protocol, the final OS analysis was to occur upon observing ~248 events; 252 events (122 with InO and 130 with SC) were observed on March 8, 2016; data as of this date are presented.


Results


The ITT analysis population included 326 patients with both arms being well balanced for baseline stratification factors. The OS hazard ratio (HR) between InO and SC was 0.77 (97.5% CI, 0.58‒1.03) with 1-sided P=0.0203 and median OS 7.7 [95% CI, 6.0‒9.2] vs 6.7 [95% CI, 4.9‒8.3] months. The second primary objective of demonstrating a statistically significant improvement in final OS with InO vs SC was not met at prespecified significance level of 0.0104. The 2-year OS rate for InO vs SC was 23% (95% CI, 16‒30%) vs 10% (95% CI, 5‒16%). It was noted, however, that the OS departed from the proportional hazards assumption. Given this, a restricted mean survival time (RMST) analysis was applied and showed: mean OS was 13.9 months for InO vs 9.9 months for SC, a difference that met statistical significance. PFS was significantly longer with InO vs SC (HR, 0.45 [97.5% CI, 0.34‒0.61]; 1-sided P<0.0001), with median PFS 5.0 [95% CI, 3.7‒5.6] vs 1.8 [95% CI, 1.5‒2.2] months. Follow-up of previously reported endpoints, including objective response, MRD-negativity, and SCT rates were all superior in the InO arm compared to the SC arm by protocol-specified criteria. Updated safety results demonstrate a tolerability and toxicity profile consistent with that reported previously.


Conclusion

Compared with SC, InO provided evidence of longer OS and significantly prolonged PFS in adult patients with R/R ALL.

대기뉴스이거나 송고가 되지 않도록 설정됨
데일리메디 dailymedi@dailymedi.com
이기자의 다른뉴스보기
무통장입금 정보입력 입금자명 입금예정일자
(입금하실 입금자명 + 입금예정일자를 입력하세요)
[관련뉴스]
- 관련뉴스가 없습니다.
트위터로 보내기 싸이월드 공감
기사글확대 기사글축소 기사스크랩 이메일문의 프린트하기
방문석 교수(서울대병원 재활의학과), 세계재활의학회 국제교류위원장
고도일 서초구의사회장, 심평원 감사패
백광호·방창석 교수(한림대춘천성심 소화기내과), 한국과학기술총연합 과학기술우수논문상
서울대병원 내과과장윤정환·외과과장 박규주 外 진료과장
김희봉 국립춘천병원 서무과장 外 복지부 과장급
유희철 교수(전북대병원 간담췌이식혈관외과), 아시아정맥경장학회 우수논문상
인터엠디 운영사 (주)디포인트→(주)인터엠디컴퍼니 변경
조성연 교수(서울성모병원 감염내과), 국제면역저하환자학회 Travel Grant상
한영근 교수(보라매병원 안과), 한국백내장굴절수술학회 학술상
이국종 교수(아주대병원), 해경 홍보대사 위촉
한희철 한국의과대학·의학전문대학원협회(KAMC) 이사장 연임
황성욱 수원 참피부비뇨기과 원장 별세
박은지 원진성형외과 실장 시모상
심재학 심재학정형외과 원장 모친상